## PubMed-cited research articles on the Middle East respiratory syndrome

Yaseen Arabi, Ahmad M. Deeb<sup>1</sup>, Hanan Ageel<sup>1</sup>, Hanan Balkhy<sup>2</sup>

Department of Intensive Care, King Saud Bin Abdulaziz University. King Abdulaziz Medical City, Ministry of National Guard Health Affairs, <sup>1</sup>King Abdullah International Medical Research Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, <sup>2</sup>Infection Control Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia

Address for correspondence:

Prof. Yaseen Arabi,
Department of Intensive
Care, King Saud Bin
Abdulaziz University, King
Abdulaziz Medical City,
Ministry of National Guard
Health Affairs, Riyadh,
Kingdom of Saudi Arabia.
E-mail: arabi@ngha.med.sa

Submission: 06-12-2015 Accepted: 12-12-2015

Access this article online

Quick Response Code:



Website: www.thoracicmedicine.org

**DOI:** 10.4103/1817-1737.180024

fter more than 3 years of the first reported case of the Middle East respiratory syndrome coronavirus (MERS),[1] we sought to examine the number of PubMed-cited articles on MERS from Saudi Arabia (the most affected country)[2] and other countries. We conducted a PubMed search on November 15, 2015 using the following search keywords: MERS, MERS-CoV, Human Coronavirus-Erasmus Medical Center (HCoV-EMC), Erasmus Medical Center/2012 (EMC), HCoV-EMC/2012, novel coronavirus, and human coronavirus. We classified the articles according to the affiliation of the authors: Articles from Saudi Arabia if all authors are from Saudi Arabia, collaborative articles if the authors are from different

countries and at least one author from Saudi Arabia, or articles from non-Saudi Arabia. In addition, we classified the articles into the following categories: Diagnosis, epidemiology, virology/pathogenesis, treatment, prevention, review/commentary/editorial/experiences, animal models, transmission, and social (including health care providers and public). We identified a total of 634 articles on MERS [Table 1]. Of those, 70 (11%) were from Saudi Arabia, 56 (8.8%) were collaborative articles, and 508 (80.1%) from non-Saudi Arabia. The most common article categories in descending order were reviews/commentary/editorial/experiences 215 (33.9%) followed by epidemiology

Table 1: Number and categories of PubMed-cited articles on Middle East respiratory syndrome

Variable	All ( <i>n</i> =634)	Saudi Arabia (n=70)	Collaborative articles (n=56)	Other countries (n=508)
Year <i>n</i> (%)				
2012	16 (2.5)	2 (2.9)	3 (5.4)	11 (2.2)
2013	158 (24.9)	14 (20)	9 (16.1)	135 (26.6)
2014	250 (39.4)	32 (45.7)	26 (46.4)	192 (37.8)
2015	210 (33.1)	22 (31.4)	18 (32.1)	170 (33.4)
Main category n (%)				
Reviews/commentary/ editorial/experiences	215 (33.9)	40 (57.1)	14 (25)	161 (31.7)
Epidemiology	119 (18.8)	19 (27.2)	16 (28.6)	84 (16.5)
Transmission	80 (12.6)	2 (2.9)	17 (30.3)	61 (12)
Virology	78 (12.3)	1 (1.4)	5 (8.9)	72 (14.2)
Treatment	55 (8.7)	4 (5.7)	0 (0)	51 (10)
Diagnosis	32 (5)	0 (0)	1 (1.8)	31 (6.1)
Prevention	29 (4.6)	1 (1.4)	0 (0)	28 (5.5)
Animal models	18 (2.8)	0 (0)	1 (1.8)	17 (3.4)
Social studies	8 (1.3)	3 (4.3)	2 (3.6)	3 (0.6)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

**How to cite this article:** Arabi Y, Deeb AM, Aqeel H, Balkhy H. PubMed-cited research articles on the Middle East respiratory syndrome. Ann Thorac Med 2016;11:112-3.

## Arabi, et al.: Pub-Med MERS-COV

119 (18.8%), MERS transmission 80 (12.6%), and virology 78 (12.3%). To date, there is no definite therapy or vaccine for MERS-CoV infection. Multiple studies were conducted to discover potential treatment, 55 (8.7%) or prevention/vaccine, 29 (4.6%) for MERS-CoV. However, there is no randomized controlled trial so far. The number of social studies, describing the knowledge, perceptions, or attitudes toward MERS or provide educational activities is very limited. These numbers contrast with what has happened with the severe acute respiratory syndrome (SARS), wherein 33 months of the onset of the outbreak, there were 2854 PubMed publications, 33 of which were clinical trials. [3] This literature search highlights

the urgent need for further research on MERS, which requires high level of collaboration.

## References

- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.
- World Health Organization: Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available from: http://www.who. int/emergencies/mers-cov/en/. [Last cited on 2015 Nov 29].
- 3. Perl TM, Price CS. Orchestrated scientific collaboration: Critical to the control of MERS-CoV. Ann Intern Med 2015;163:313-4.